Report ID : 10082827 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Antihypertensive Drugs Market Scope
|
Base Year |
2021 |
|
Forecast Year |
2022-2031 |
|
CAGR |
~3% |
|
Base Year Market Size (2021) |
~ USD 20 Billion |
|
Forecast Year Market Size (2031) |
~ USD 40 Billion |
Global Antihypertensive Drugs Market Size, Forecast, and Trend Highlights Over 2022 - 2031
The global antihypertensive drugs market is estimated to garner a revenue of approximately USD 40 billion by the end of 2031 by growing at a CAGR of around ~3% over the forecast period, i.e., 2022 – 2031. Further, the market generated a revenue of nearly USD 20 billion in the year 2021. This expansion in market size is attributed to a staggering rise in the incidence of hypertension across the globe. As per the data published by the World Health Organization (WHO) in 2021, it has reported that around 1.28 billion adults have hypertension, with almost two-thirds of them living in low- and middle-income countries.
Source – Kenneth Research
GET A SAMPLE COPY OF THIS REPORT
Hypertension is a medical condition that involves a rise in blood pressure in the arteries. A patient suffering from hypertension is susceptible to other complications like heart failure, heart attack, kidney failure, aneurysm, and others. Hence, the treatment of hypertension requires early diagnosis and management with the use of antihypertensive drugs. Some of the antihypertensive drugs class available on the market include diuretics, beta-blockers, calcium channel blockers, ACE inhibitors, vasodilators, and others. Moreover, they help to control the high incidence of hypertension mortality rate across the globe. For instance, almost half of the adults in the US alone (~47% of the population) suffer from hypertension, according to the Centers for Disease Control and Prevention (CDC), and over 670,000 deaths occurred in the year 2020 had hypertension as a primary factor.
Global Antihypertensive Drugs Market: Growth Drivers and Challenges
Growth Drivers
-
Rise in the Number of Cardiovascular Diseases – Nearly 17.9 million people across the globe died from cardiovascular diseases in 2019, according to a study published by the World Health Organization
-
High Dietary Salt Intake – An increase in dietary sodium has been linked to higher blood pressure which leads to a greater incidence of cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) asserts that about 90% of Americans consume more than the recommended daily intake of sodium which is less than 2300 mg.
-
Expanding Geriatric Population – There has been a greater demand for antihypertensive drugs that control blood pressure in older patients. Therefore, it is expected to drive the growth of the global antihypertensive drugs market. As per the statistics provided by the United States Census Bureau in 2020, there has been a dramatic increase in the nation’s 65-and-older population since 2010, growing by about ~34%.
-
Increased Awareness About Complications Related to Hypertension - Increasing public awareness about the ill effects of hypertension and early screening of the disease are expected to bridge this gap and propel the global antihypertensive drugs market growth. According to a study published by the NIH, only about ~50% of people with hypertension were aware of their condition, and only ~72% of them were using antihypertensive drugs prescribed by physicians.
Challenges
-
Expiration of Patents Leading to an Increase in Cheaper Copies of Original Drugs in the Market
-
Strict Regulations for the Approval of New Drugs
-
Lack of Awareness Among the People Related to Hypertension Symptoms
The global antihypertensive market is segmented and analyzed for demand and supply by drug class into calcium channel blockers, ACE inhibitors, adrenergic blockers, angiotensin II receptor blockers, diuretics, vasodilators, and others. Of these, the ACE Inhibitors segment is expected to exhibit the fastest growth over the forecast period owing to its benefits of lowering blood pressure by relaxing the veins and arteries. Moreover, they are not only effective in the treatment of hypertension but also help in treating other diseases like diabetes and chronic kidney diseases. For instance, chronic kidney diseases (CKD) affect more than 1 in 7 U.S. adults, which is an estimated 37 million Americans, according to the data stated by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2021.
Global Antihypertensive Drugs Market Regional Synopsis
Regionally, the global antihypertensive drugs market is categorized into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions. Amongst these, the market in North America region is projected to hold the largest market share by the end of 2031 owing of easy access to antihypertensive drug therapy, a rise in the geriatric patient pool, and higher levels of obesity that lead to an increase in the occurrence of hypertension among its population. Obesity in the United States increased from 30.5% to 41.9% from 1999-2000 to 2017-2020, as per the National Health and Nutrition Examination Survey (NHANES).
However, the market in the Asia-Pacific region is expected to grow at a faster rate during the forecast period, owing to an increasing awareness related to hypertension and the use of antihypertensive drugs. The booming biotechnological, pharmaceutical and life sciences industries are projected to propel the growth of the market in developing economies such as India, China, and Malaysia. For instance, India's domestic pharmaceutical market was valued at USD 42 Billion in 2021 and is likely to reach an approximate value of USD 120 Billion during the time span studied, according to the India Brand Equity Foundation (IBEF).
Market Segmentation
Our in-depth analysis of the global antihypertensive drugs market includes the following segments:
|
By Drug Class |
|
|
By Distribution Channel |
|
Key Companies Dominating the Global Antihypertensive Drugs Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global antihypertensive drugs market that are included in our report are AstraZeneca, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc., Merck KGaA, Bayer AG, Lupin Limited, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Medtronic, and others.
Global Antihypertensive Drugs Market: Latest Developments
-
May 17, 2022: Medtronic announced the benefits related to the Symplicity Blood Pressure Procedure with the Symplicity Spyral Renal Denervation (RDN) system that helps to achieve target blood pressure level ranges.
-
July 30, 2021: Johnson & Johnson Services, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the UPTRAVI (selexipag) injection for intravenous (IV) use in adult patients with WHO functional class (FC) II-III who are temporarily unable to take oral therapy.
Key Reasons to Buy Our Report
-
The report covers a detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis, and challenges that impact market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessments for overall growth.
-
We provide customized reports as per the client’s requirements helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goals.
